ACTU vs EXPE · $49.0M cap vs P/E 20, rev $7.74B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
ACTU currently screens at market cap $49.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the ACTU and EXPE stock pages for the full models.
Not investment advice.